Trial Profile
A multi-centre long-term follow-up study of patients with low-grade non-Hodgkin's lymphoma previously treated with tositumomab and/or iodine I 131 tositumomab in studies RIT-I-000, RIT-II-001, RIT-II-002, or CP-97-012
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jun 2023
Price :
$35
*
At a glance
- Drugs Iodine-131 tositumomab (Primary) ; Tositumomab
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 09 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 31 Mar 2008 New trial record.